SE0002531D0 - Immune Enhancement - Google Patents

Immune Enhancement

Info

Publication number
SE0002531D0
SE0002531D0 SE0002531A SE0002531A SE0002531D0 SE 0002531 D0 SE0002531 D0 SE 0002531D0 SE 0002531 A SE0002531 A SE 0002531A SE 0002531 A SE0002531 A SE 0002531A SE 0002531 D0 SE0002531 D0 SE 0002531D0
Authority
SE
Sweden
Prior art keywords
butyl
pentyl
iso
propyl
methyl
Prior art date
Application number
SE0002531A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Gunnar Hedlund
Tomas Leandersson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0002531A priority Critical patent/SE0002531D0/xx
Publication of SE0002531D0 publication Critical patent/SE0002531D0/xx
Priority to PCT/SE2001/001526 priority patent/WO2002002511A1/en
Priority to DE60106036T priority patent/DE60106036T2/de
Priority to JP2002507768A priority patent/JP4864273B2/ja
Priority to EP01958717A priority patent/EP1299350B1/en
Priority to AT01958717T priority patent/ATE277890T1/de
Priority to AU2001280338A priority patent/AU2001280338A1/en
Priority to CA002414146A priority patent/CA2414146C/en
Priority to PT01958717T priority patent/PT1299350E/pt
Priority to ES01958717T priority patent/ES2230350T3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0002531A 2000-07-05 2000-07-05 Immune Enhancement SE0002531D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0002531A SE0002531D0 (sv) 2000-07-05 2000-07-05 Immune Enhancement
PCT/SE2001/001526 WO2002002511A1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
DE60106036T DE60106036T2 (de) 2000-07-05 2001-07-03 Substituierte Benzamide für die Immunstärkung, die Behandlung von Krebs, Infektionen und manisch-depressiven Erkrankungen
JP2002507768A JP4864273B2 (ja) 2000-07-05 2001-07-03 免疫強化並びに癌、感染および躁鬱病の治療のための置換ベンズアミド
EP01958717A EP1299350B1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
AT01958717T ATE277890T1 (de) 2000-07-05 2001-07-03 Substituierte benzamide für die immunstärkung, die behandlung von krebs, infektionen und manisch-depressive erkrankungen
AU2001280338A AU2001280338A1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
CA002414146A CA2414146C (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
PT01958717T PT1299350E (pt) 2000-07-05 2001-07-03 Benzamidas substituidas para o aumento de imunidade e para o tratamento do cancro, infeccoes e da doenca manioco-depressiva
ES01958717T ES2230350T3 (es) 2000-07-05 2001-07-03 Benzamidas sustituidas para aumento de la respuesta inmune y para el tratamiento de cancer, enfermedad infecciosa y maniaco-depresiva.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002531A SE0002531D0 (sv) 2000-07-05 2000-07-05 Immune Enhancement

Publications (1)

Publication Number Publication Date
SE0002531D0 true SE0002531D0 (sv) 2000-07-05

Family

ID=20280373

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002531A SE0002531D0 (sv) 2000-07-05 2000-07-05 Immune Enhancement

Country Status (10)

Country Link
EP (1) EP1299350B1 (OSRAM)
JP (1) JP4864273B2 (OSRAM)
AT (1) ATE277890T1 (OSRAM)
AU (1) AU2001280338A1 (OSRAM)
CA (1) CA2414146C (OSRAM)
DE (1) DE60106036T2 (OSRAM)
ES (1) ES2230350T3 (OSRAM)
PT (1) PT1299350E (OSRAM)
SE (1) SE0002531D0 (OSRAM)
WO (1) WO2002002511A1 (OSRAM)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE620543A (OSRAM) *
FR1525M (fr) * 1961-07-25 1962-11-16 Ile De France Médicaments antiémétiques nouveaux.
ES404497A1 (es) * 1972-06-20 1975-06-01 Miquel S A Lab Procedimiento para la obtencion de derivados de benzoileti-lendiaminas sustituidas.
EP0117462A3 (en) * 1983-02-28 1986-08-20 American Cyanamid Company N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides
US4568685A (en) * 1984-02-29 1986-02-04 American Cyanamid Company N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
CA2074061A1 (en) * 1991-08-26 1993-02-27 Ivo Monkovic Benzamide multidrug resistance reversing agents
AU6167696A (en) * 1995-06-07 1996-12-30 Dade Chemistry Systems Inc. Preparation of immunogens and other conjugates of drugs
US6100299A (en) * 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
JP3933244B2 (ja) * 1997-04-04 2007-06-20 株式会社資生堂 アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤
JPH1180107A (ja) * 1997-09-01 1999-03-26 Japan Tobacco Inc 骨形成促進剤及びアミド化合物
JP2001151742A (ja) * 1999-11-26 2001-06-05 Mitsui Chemicals Inc アニリド誘導体及びそれを含有する抗不整脈剤

Also Published As

Publication number Publication date
EP1299350A1 (en) 2003-04-09
EP1299350B1 (en) 2004-09-29
PT1299350E (pt) 2005-01-31
AU2001280338A1 (en) 2002-01-14
JP4864273B2 (ja) 2012-02-01
CA2414146A1 (en) 2002-01-10
WO2002002511A1 (en) 2002-01-10
CA2414146C (en) 2008-11-25
DE60106036D1 (de) 2004-11-04
ES2230350T3 (es) 2005-05-01
JP2004502668A (ja) 2004-01-29
ATE277890T1 (de) 2004-10-15
DE60106036T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
ES2121441T3 (es) Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
NL300877I2 (nl) obeticholzuur
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
NZ543897A (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
HUP0303326A2 (hu) Benzofenonszármazékok, mint reverz transzkriptáz inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
ATE375984T1 (de) Chinazolin derivate
BR0213731A (pt) Compostos de silìcio
RU2007116987A (ru) Новые соединения
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
NZ519126A (en) Novel IL-8 receptor antagonists
JO2235B1 (en) Derivatives of phenyl
JO2307B1 (en) Papermidine derivatives
AU2001280338A1 (en) Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
EA200700871A1 (ru) Способы нейропротекции
TR199801774T2 (xx) 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
RO114615B1 (ro) Derivaţi ciclici ai acidului aminofenilacetic cu acţiune imunomodulatoare, procedee de preparare şi intermediari în sinteza acestora
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
RU95110868A (ru) Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция
EA200200352A1 (ru) Фенил- и пиридил-тетрагидропиридины, обладающие ингибирующей активностью в отношении фактора некроза опухоли (фно)
RU2412195C2 (ru) Новые соединения, производные от 5-тиоксилозы, и их терапевтическое применение
SE9700803L (sv) Farmaceutisk komposition för behandling av s k restless legs